All Psychedelic Research Papers

This page displays all psychedelic research papers in Blossom’s database in one list.

To use all the search functionalities available on Blossom, see our Psychedelic Research Papers Search page.

Or navigate to one of our other databases | Courses Search (List) | Books Search (List) | People Search (List) | Companies Search (List) | Videos Search (List) | Measures Search (List) | Trials Search (List) | Events Search (List) | Compounds Overview (List) | Topics Overview (List) | Countries Overview (List)

All Psychedelic Research Papers List

• Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants
• Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation
• Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
• Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States
• Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study
• Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial
• Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions
• Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
• Time-resolved neural and experience dynamics of medium- and high-dose DMT
• DMT micro-phenomenology
• Psilocybin increases emotional empathy in patients with major depression
• The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
• An investigation of acute Physiological and Psychological Moderators of Psychedelic-induced Personality Change among Healthy Volunteers
• Health Care Workers’ Attitudes Toward and Knowledge of the Clinical Application of Classic Psychedelics for People with Serious Illness: A Systematic Review
• The Australia story: Current status and future challenges for the clinical applications of psychedelics
• Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants
• Quality of reporting on psychological interventions in psychedelic treatments: a systematic review
• Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
• Practical considerations in the establishment of psychedelic research programs
• Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic
• Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
• Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial
• Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study
• Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study
• Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis
• Structural neural plasticity evoked by rapid-acting antidepressant interventions
• Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder
• Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study
• Safety pharmacology of acute mescaline administration in healthy participants
• MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis
• Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies
• Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically
• Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study
• The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD
• Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials
• Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task
• Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial
• Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use
• Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model
• Pyramidal cell types and 5-HT2A receptors are essential for psilocybin’s lasting drug action
• Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study
• Effects of a Serotonergic Psychedelic on the Lipid Bilayer
• Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, proof-of-concept clinical trial
• Rapid Effects of MDMA Administration on Self-Reported Personality Traits and Affect State: A Randomized, Placebo-Controlled Trial in Healthy Adults
• Acceptance as a possible link between past psychedelic experiences and psychological flexibility
• Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing
• The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression
• The non-hallucinogenic serotonin 1B receptor is necessary for the antidepressant-like effects of psilocybin in mice
• Outcomes and physiologic responses associated with ketamine administration after traumatic brain injury in the United States and Canada: a retrospective analysis
• The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin
• Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey
• Complex slow waves radically reorganise human brain dynamics under 5-MeO-DMT
• Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome
• Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging
• Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans
• Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects
• Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study
• Entactogen Effects of Ketamine: A Reverse-Translational Study
• Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat
• A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers
• Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being
• Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response
• Single-dose 1cp-LSD administration for canine anxiety: a pilot study
• Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
• Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study
• The psychedelic personality: Personality structure and associations in a sample of psychedelics users
• States and traits related to the quality and consequences of psychedelic experiences
• Modulatory effects of ayahuasca on personality structure in a traditional framework
• Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine
• Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
• Reported effects of psychedelic use on those with low well-being given various emotional contexts
• An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States
• Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide
• Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
• Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials
• Distinct 5-HT receptor subtypes regulate claustrum excitability by serotonin and the psychedelic, DOI
• Clinically relevant acute subjective effects of psychedelics beyond mystical experience
• Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis
• Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants
• Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study
• Low-Dose LSD Alters Early and Late Event-Related Potentials to Emotional Faces
• Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
• Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation
• An Integrated theory of false insights and beliefs under psychedelics
• Psilocybin-assisted therapy and HIV-related shame
• Preferences and Attitudes Toward Music in Nonclinical Uses of Psychedelics
• Experiences of psychedelic drug use among people with psychotic symptoms and disorders: Personal growth and mystical experiences
• 5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics
• Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate”
• A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
• LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up
• Clinical Utility of fMRI in Evaluating of LSD Effect on Pain-Related Brain Networks in Healthy Subjects
• Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy
• Inter-individual variability in neural response to low doses of LSD
• Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)
• 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes
• Rapid effects of tryptamine psychedelics on perceptual distortions and early visual cortical population receptive fields
• Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy
• Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in rats
• Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT) 2A and 5-HT2C receptors
• Psilocybin and 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) at Encoding Distort Episodic Familiarity
• Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A
• Do classic psychedelics increase the risk of seizures? A scoping review
• A Transformative Trip? Experiences of Psychedelic Use
• Purging to cleanse: a qualitative study of Ayahuasca healing at a drug treatment centre in Peru
• Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience
• Bioisosteric analogs of MDMA: Improving the pharmacological profile?
• Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT
• Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems
• The Role of Music in Psychedelic-Assisted Therapy: A Comparative Analysis of Neuroscientific Research, Indigenous Entheogenic Ritual, and Contemporary Care Models
• Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement
• Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression
• Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives
• Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial
• Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT)
• Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users
• The Influence of Psilocybin on Subconscious and Conscious Emotional Learning
• Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy
• AlphaFold2 structures guide prospective ligand discovery
• Intranasal ketamine for acute cluster headache attacks—Results from a proof-of-concept open-label trial
• Experiences of Awe Mediate Ketamine’s Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression
• Investigating the relationship between changes in metaphysical beliefs and death anxiety following a significant psychedelic experience
• How Do Psychedelics Reduce Fear of Death?
• Navigating Groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences
• Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression
• LSD flattens the hierarchy of directed information flow in fast whole-brain dynamics
• Structural pharmacology and therapeutic potential of 5-methoxytryptamines
• Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study
• Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance
• The Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies
• Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions
• Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis
• Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks
• Chemical cousins with contrasting behavioural profiles: MDMA users and methamphetamine users differ in social-cognitive functions and aggression
• The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli
• Ketamine induces multiple individually distinct whole-brain functional connectivity signatures
• Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
• Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm
• Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
• Methyl transfer in psilocybin biosynthesis
• Trauma Under Psychedelics: MDMA Shows Protective Effects During the Peritraumatic Period
• Getting in Touch with Touch: The Importance of Studying Touch in MDMA-Assisted Therapy and the Development of a New Self-Report Measure
• Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants
• A dual-receptor model of serotonergic psychedelics: therapeutic insights from simulated cortical dynamics
• Psychedelics and the ‘inner healer’: Myth or mechanism?
• The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
• Naturalistic use of psychedelics does not modulate processing of self-related stimuli (but it might modulate attentional mechanisms): An event-related potentials study
• Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
• Oral prolonged-release ketamine in treatment-resistant depression – A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation – Clinical and safety results
• Effects of psychedelics in older adults: A prospective cohort study
• Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation
• Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis
• Brain substates induced by DMT relate to sympathetic output and meaningfulness of the experience
• Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
• Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties
• Adolescent Psychedelic Use and Psychotic or Manic Symptoms
• The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
• Safety pharmacology of acute psilocybin administration in healthy participants
• Salience, Sensemaking, and Setting in Psilocybin Microdosing: Methodological Lessons and Preliminary Findings of a Mixed Method Qualitative Study
• IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital
• The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients
• Childhood trauma, challenging experiences, and posttraumatic growth in ayahuasca use
• Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression
• Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
• Perceived attachment history predicts psychedelic experiences: A naturalistic study
• Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes
• Conflict monitoring and emotional processing in 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine users – A comparative neurophysiological study
• Synthetic surprise as the foundation of the psychedelic experience
• Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity
• Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations
• Expectancy effects in psychedelic trials
• A proof-of-principle study of the short-term effects of 3,4-methylenedioxymethamphetamine (MDMA) on tinnitus and neural connectivity
• Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
• Effects of Psychedelic Microdosing versus Conventional ADHD Medication Use on Emotion Regulation, Empathy, and ADHD Symptoms in Adults with severe ADHD symptoms: A Naturalistic Prospective Comparison Study
• Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study
• Psychedelics-assisted psychotherapy: Experiences with the limited medical use of LSD, MDMA, and psilocybin in Switzerland
• Exploring mechanisms of psychedelic action using neuroimaging
• Processing of self-related thoughts in experienced users of classic psychedelics and non-users: a source localisation EEG study
• What Predicts Beneficial Outcomes in Psychedelic Use? A Quantitative Content Analysis of Psychedelic Health Outcomes
• Subjective long-term emotional and social effects of recreational MDMA use: the role of setting and intentions
• Who Are You After Psychedelics? A Systematic Review and a Meta-Analysis of the Magnitude of Long-Term Effects of Serotonergic Psychedelics on Cognition/Creativity, Emotional Processing and Personality
• Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study
• Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA
• Effects of DMT on mental health outcomes in healthy volunteers
• Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial
• Psychedelics and sexual functioning: a mixed-methods study
• Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
• Effects of hallucinogenic drugs on the human heart
• DMT induces a transient destabilization of whole-brain dynamics
• Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine
• Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial
• MDMA enhances positive affective responses to social feedback
• Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study
• Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression
• Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine
• Microdosing psychedelics: Current evidence from controlled studies
• A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
• Older adults in psychedelic-assisted therapy trials: A systematic review
• Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression
• The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression
• Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
• Coming back together: A qualitative survey study of coping and support strategies used by people to cope with extended difficulties after the use of psychedelic drugs
• So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
• Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
• Spiritual health practitioners’ contributions to psychedelic assisted therapy: A qualitative analysis
• Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment
• Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder
• Magnesium–ibogaine therapy in veterans with traumatic brain injuries
• Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
• The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
• Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial
• The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database
• Personality traits explain the relationship between psychedelic use and less depression in a comparative study
• Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
• Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study
• The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis
• Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis
• Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder
• Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
• Anti-suicidal effects of IV ketamine in a real-world setting
• Treatment with psychedelics is psychotherapy: beyond reductionism
• 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study
• The relation between naturalistic use of psychedelics and perception of emotional stimuli: An event-related potential study comparing non-users and experienced users of classic psychedelics
• Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model
• Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes
• 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
• Must Psilocybin Always “Assist Psychotherapy”?
• Group psychedelic therapy: empirical estimates of cost-savings and improved access
• Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans
• Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study
• Greater subjective effects of a low dose of LSD in participants with depressed mood
• The Integration of Classic Psychedelics into Current Substance Use Disorder Treatment Models
• Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists
• Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder
• Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: a retrospective survey
• Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine
• Drug-drug interactions involving classic psychedelics: A systematic review
• Spiritual Well-Being Among Users and Non-Users of Psychedelics: A Cross-Sectional Study
• Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample
• Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview
• Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
• Cellular rules underlying psychedelic control of prefrontal pyramidal neurons
• Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis
• Ayahuasca ceremony leaders’ perspectives on special considerations for eating disorders
• The entropic heart: Tracking the psychedelic state via heart rate dynamics
• When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
• Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action
• Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study
• Dynamic Functional Hyperconnectivity after Psilocybin Intake is Primarily Associated with Oceanic Boundlessness
• Psychedelic-assisted psychotherapy: Where is the psychotherapy research?
• Psychiatric risks for worsened mental health after psychedelic use
• Psychedelic use and psychiatric risks
• The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
• Does MDMA have treatment potential in sexual dysfunction? A systematic review of outcomes across the female and male sexual response cycles
• Effects of a dissociative drug on fronto-limbic resting-state functional connectivity in individuals with posttraumatic stress disorder: a randomized controlled pilot study
• Cortical structural differences following repeated ayahuasca use hold molecular signatures
• Extended difficulties following the use of psychedelic drugs: A mixed methods study
• LSD-induced changes in the functional connectivity of distinct thalamic nuclei
• Ketamine’s acute effects on negative brain states are mediated through distinct altered states of consciousness in humans
• Naturalism and the hard problem of mysticism in psychedelic science
• Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression
• Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom
• Psilocybin-assisted neurofeedback for the improvement of executive functions: a semi-naturalistic-lab feasibility study
• Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
• Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression
• Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis
• Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use
• Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists
• Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences
• Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
• A suite of engineered mice for interrogating psychedelic drug actions
• Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
• Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results
• The ego in psychedelic drug action – ego defenses, ego boundaries, and the therapeutic role of regression
• Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
• Ayahuasca, Personality and Acute Psychological Effects in Neo-Shamanic and Religious Settings in Uruguay
• Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
• Alternative beliefs in psychedelic drug users
• Attention deficit hyperactivity disorder symptoms and lifetime use of psychoactive substances among French university students: A cross-sectional study
• History repeating: guidelines to address common problems in psychedelic science
• Early effects predict trajectories of response to esketamine in treatment-resistant depression
• Neuroplasticity: The Continuum of Change
• Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans
• American Psychiatrists’ Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey
• Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program
• Ketamine use in pediatric depression: A systematic review
• Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders
• The Psychedelic N,N-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors
• Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations
• Psychedelics and the neurobiology of meaningfulness
• Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
• Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
• Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
• Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic
• MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
• Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework
• Predictors of psychedelic treatment outcomes among special operations forces veterans
• MDMA-assisted psychotherapy with adolescents suffering from PTSD: Do or don’t? a qualitative study with youth, parents, and clinicians
• MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy
• The flattening of spacetime hierarchy of the N,N-dimethyltryptamine brain state is characterized by harmonic decomposition of spacetime (HADES) framework
• MDMA Assisted Psychotherapy Decreases PTSD Symptoms, Dissociation, Functional Disability, and Depression: A Systematic Review and Meta-Analysis
• Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study
• Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
• Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences
• A quantitative textual analysis of the subjective effects of ayahuasca in naive users with and without depression
• Ayahuasca Treatment Outcome Project (ATOP): One Year Results from Takiwasi Center and Implications for Psychedelic Science
• Psilocybin desynchronizes the human brain
• Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers
• Psychedelic Intimacy: Altered States of Consciousness in Romantic Relationships
• Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
• Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
• Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics
• Identification of 5-HT 2A Receptor Signaling Pathways Responsible for Psychedelic Potential
• Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States
• The Therapeutic Alliance in Psychedelic-Assisted Psychotherapy: A Novel Target for Research and Interventions
• Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide (LSD) administration in healthy participants
• Ketamine for the treatment of major depression: a systematic review and meta-analysis
• Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey
• The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
• Microdosing psychedelics has no impact on cognitive function in naturalistic settings
• Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
• Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
• Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies
• The Potential of Psychedelics for the Treatment of Episodic Migraine
• A phenomenological analysis of Fellini’s films to understand the effect of LSD therapy on his creativity
• The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada
• Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance
• Effective-connectivity of thalamocortical interactions following d-amphetamine, LSD, and MDMA administration
• The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing
• Therapeutic mechanisms of psychedelics and entactogens
• Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: a systematic review and individual participant data meta-analysis
• Effects of psychedelics on neurogenesis: A systematic review of pre-clinical studies
• A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
• Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials
• Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis
• Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
• Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)
• The Relationship Between the Default Mode Network and the Theory of Mind Network as Revealed by Psychedelics– A Meta-Analysis
• Comparing neural correlates of consciousness: from psychedelics to hypnosis and meditation
• Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
• The potential of psychedelics for the treatment of Alzheimer’s disease and related dementias
• N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q)
• Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial
• Perceived key change phenomena of MDMA-assisted psychotherapy for the treatment of severe PTSD: an interpretative phenomenological analysis of clinical integration sessions
• A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)
• Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD
• MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations
• Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans
• Psilocybin’s effects on cognition and creativity: A scoping review
• Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
• A complex systems perspective on psychedelic brain action
• Navigating the chaos of psychedelic neuroimaging: A multi-metric evaluation of acute psilocybin effects on brain entropy
• The power of insight: How psychedelics solicit false beliefs
• Harnessing placebo: Lessons from psychedelic science
• Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms
• Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis
• Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca
• Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
• Life after Ayahuasca: A Qualitative Analysis of the Psychedelic Integration Experiences of 1630 Ayahuasca Drinkers from a Global Survey
• Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics
• Long term structural and functional neural changes following a single infusion of Ketamine in PTSD
• Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use
• LSD increases sleep duration the night after microdosing
• Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021
• Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial
• Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis
• Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey
• Psychedelic Experiences After Bereavement Improve Symptoms of Grief: The Influence of Emotional Breakthroughs and Challenging Experiences
• A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
• Chronic 3,4-Methylenedioxymethamphetamine (MDMA) use is related to glutamate and GABA concentrations in the striatum, but not in the anterior cingulate cortex
• Bridging the translational neuroscience gap: Development of the ‘shiftability’ paradigm and an exemplar protocol to capture psilocybin-elicited ‘shift’ in neurobiological mechanisms in autism
• Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia
• Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline
• The effects of ketamine on symptoms of depression and anxiety in real-world care settings: a retrospective controlled analysis
• Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis
• Unlocking the self: Can microdosing psychedelics make one feel more authentic?
• Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
• Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression
• Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants
• Effects of ayahuasca on gratitude and relationships with nature: An open-label, naturalistic study
• HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer
• Psychedelics reopen the social reward learning critical period
• Effect of LSD and music on the time-varying brain dynamics
• Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
• Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research
• Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
• Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model
• Psychedelic therapy in the treatment of addiction: the past, present and future
• Ayahuasca in the treatment of bipolar disorder with psychotic features–A retrospective case study
• Changed Substance Use After Psychedelic Experiences Among Individuals in Canada
• Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
• Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
• Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial
• Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth
• Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
• Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
• Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience
• Increases in aesthetic experience following ayahuasca use: An open-label, naturalistic study
• The Bodily Self from Psychosis to Psychedelics
• Right dorsolateral prefrontal cortex volumetric reduction is associated with antidepressant effect of low-dose ketamine infusion: A randomized, double-blind, midazolam-controlled PET-MRI clinical trial
• Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression
• A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Quantitative Analysis
• Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review
• ARC: a framework for access, reciprocity and conduct in psychedelic therapies
• One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression
• Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression
• Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression
• Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users
• Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
• Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use
• Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
• How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
• Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review
• Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States
• Randomized trial of ketamine masked by surgical anesthesia in patients with depression
• Reporting of harms in clinical trials of esketamine in depression: a systematic review
• Whole-brain mapping reveals the divergent impact of ketamine on the dopamine system
• The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs
• Self-reported effects of classic psychedelics on stuttering
• Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
• A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
• “How Do I Learn More About this?”: Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics
• Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample
• Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
• A whole-brain model of the neural entropy increase elicited by psychedelic drugs
• LSD microdosing attenuates the impact of temporal priors in time perception
• Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression
• Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users
• Psychological and physiological effects of extended DMT
• Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis
• Case analysis of long-term negative psychological responses to psychedelics
• TMS-EEG and resting-state EEG applied to Altered States of Consciousness: Oscillations, Complexity, and Phenomenology
• Classical and non-classical psychedelic drugs induce common network changes in human cortex
• Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
• A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects
• Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder
• Acute mood-elevating properties of microdosed LSD in healthy volunteers: a home-administered randomised controlled trial
• View, meditation, action: A Tibetan framework to inform psychedelic-assisted therapy
• Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder
• On the need for metaphysics in psychedelic therapy and research
• Spatial correspondence of LSD-induced variations of brain functioning at rest with serotonin receptor expression
• Examining the Therapeutic Effect of Ceremonial Ayahuasca on Narcissistic Personality and Antagonistic Externalizing in Adults
• Classic Psychedelic Use and Current Meditation Practice
• Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial
• Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on Esketamine intranasal spray and covered by US commercial health plans
• Information parity increases on functional brain networks under influence of a psychedelic substance
• A Randomized Double-Blind Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation
• An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study
• ‘More evolved than you’: Evolutionary spirituality as a cultural frame for psychedelic experiences
• Human brain effects of DMT assessed via EEG-fMRI
• Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
• The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience
• Ibogaine – A legacy within the current renaissance of psychedelic therapy
• Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health
• Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study
• A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
• Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice
• Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
• The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
• Association between mystical-type experiences under psychedelics and improvements in well-being or mental health – A comprehensive review of the evidence
• Psychedelics and psychological strengths
• A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
• Spectral changes of EEG following a 6-week low-dose oral ketamine treatment in adults with major depressive disorder and chronic suicidality
• Repurposing ketamine to treat cocaine use disorder: Integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration, and mechanism of action analyses
• Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder
• Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice
• Pharmacological effects of methylone and MDMA in humans
• Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
• Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition
• Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
• The classic psychedelic DOI induces a persistent desynchronized state in medial prefrontal cortex
• N,N-dimethyltryptamine affects EEG response in a concentration dependent manner – a pharmacokinetic/pharmacodynamic analysis
• A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Qualitative Analysis of Response Data
• Therapeutic effect of psilocybin in addiction: A systematic review
• The therapeutic potential of psychedelics: the European regulatory perspective
• Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
• Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?—A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines
• Psychedelic Identity Shift: A Critical Approach to Set And Setting
• Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
• Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being
• Treating Bipolar Depression with Esketamine: Safety and Effectiveness data from a naturalistic multicentric study on Esketamine in Bipolar versus Unipolar Treatment-Resistant Depression
• Classic psychedelics do not affect T cell and monocyte immune responses
• Oral Ketamine for Depression: An Updated Systematic Review
• Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use
• Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
• Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
• Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
• Distributed harmonic patterns of structure-function dependence orchestrate human consciousness
• LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals
• Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
• Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series
• Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands
• Microdosing psychedelics – Does it have an impact on emodiversity?
• 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
• A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics
• Micro-dose, macro-impact: Leveraging psychedelics in frontline healthcare workers during the COVID-19 pandemic
• A comparison of the antianhedonic effects of repeated ketamine infusions in melancholic and non-melancholic depression
• Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity
• The association between naturalistic use of psychedelics and co-occurring substance use disorders
• “Paradoxical wakefulness” induced by psychedelic 5-methoxy-N,N-dimethyltryptamine in mice
• Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness
• Effects of MDMA-assisted therapy for PTSD on self-experience
• LSD use in the United States: Examining user demographics and their evolution from 2015-2019
• Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury
• Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms
• Canalization and plasticity in psychopathology
• Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial
• Meditation Trips: A Thematic Analysis of the Combined Naturalistic Use of Psychedelics With Meditation Practices
• Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
• Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder
• “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use
• Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics
• Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
• Adverse Events and Measurement of Dissociation after the First Dose of Esketamine in Patients with TRD
• A unified model of ketamine’s dissociative and psychedelic properties
• Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression
• Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs
• Biomarkers of ketamine’s antidepressant effect: An umbrella review
• Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants
• The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: A systematic review and meta-analysis
• Effects of MDMA and Intranasal oxytocin on social and emotional processing
• Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans
• MDMA alters emotional processing and facilitates positive social interaction
• Patients’ recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression
• Psilocybin-assisted therapy mediates psycho-social-spiritual change in cancer patients as assessed by the NIH-HEALS
• Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias
• Altered States of Consciousness During Ceremonial San Pedro Use
• Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study
• Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
• Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
• Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation
• Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
• Lower-dose psycholytic therapy – A neglected approach
• Therapeutic use of psilocybin: Practical considerations for dosing and administration
• Classic psychedelics, health behavior, and physical health
• Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences
• Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans
• The Altered States Database: Psychometric data from a systematic literature review
• Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
• Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence
• Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial
• Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
• Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
• Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior
• Predictors Of Hallucinogen Persisting Perception Disorder Symptoms, Delusional Ideation And Magical Thinking Following Naturalistic Psychedelic Use
• Body mass index (BMI) does not predict responses to psilocybin
• Dose-response relationships of LSD-induced subjective experiences in humans
• More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics
• Psychedelic-Assisted Therapy for People with Eating Disorders
• A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting
• A Psychoanalytic Perspective on Psychedelic Experience
• Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects
• Replication of distinct trajectories of antidepressant response to intravenous ketamine
• MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder
• Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study
• The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
• Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
• Serotonergic antidepressant use is associated with weaker psilocybin effects
• Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
• Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects
• MDMA-Assisted Psychotherapy for Borderline Personality Disorder
• Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity
• Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study
• Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study
• Preliminary evidence of links between ayahuasca use and the corpus callosum
• Psychedelic-supportive psychotherapy: A psychotherapeutic model for, before and beyond the medicine experience
• Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability
• Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review
• Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis
• Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial
• A rapid scoping review of harm reduction strategies for ecstasy (MDMA) users in recreational settings
• The neural basis of psychedelic action
• Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use
• Default Mode Network Modulation by Psychedelics: A Systematic Review
• α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans
• Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex
• Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects
• Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration
• Mescaline: The forgotten psychedelic
• Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
• Shared functional connectome fingerprints following ritualistic ayahuasca intake
• A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy
• Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality
• Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
• Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)
• Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
• Self-Transcendent Positive Emotions as a Potential Mechanism Underpinning the Effects of Meaningful Psychedelic Experiences on Connectedness to Nature
• Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and efficacy (REAL-ESK study)
• Research abuses against people of colour and other vulnerable groups in early psychedelic research
• Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
• Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample
• Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing
• Classic and dissociative psychedelics induce similar hyper-synchronous states in the cognitive-limbic cortex-basal ganglia system
• Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness
• A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial
• Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample
• Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates
• Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
• Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder
• Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
• Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients With Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review
• Psychedelics and mindfulness: A systematic review and meta-analysis
• Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience
• Towards an understanding of psychedelic-induced neuroplasticity
• Psychedelics and schizophrenia: Distinct alterations to Bayesian inference
• LSD response in Eysenckian trait types identified by polypredictive CFA
• A long trip into the universe: Psychedelics and space travel
• Neural mechanisms of psychedelic visual imagery
• Population pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine – implications for dose considerations
• Neural Mechanisms of Resting-State Networks and the Amygdala underlying the Cognitive and Emotional Effects of Psilocybin
• International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
• Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD
• Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
• Microdosing psilocybin for chronic pain: a case series
• Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression
• A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?
• Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
• Predictors of attitudes toward psychedelics among psychologists in the USA
• Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study
• Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study
• Ketogenic diet and ketamine infusion treatment to target chronic persistent eating disorder psychopathology in anorexia nervosa: a pilot study
• Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder
• Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
• LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics
• Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying
• Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
• Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
• A feasibility study of low-dose ketamine for acute management of suicidal ideation
• Psychedelics as potent anti-inflammatory therapeutics
• Awe as a Pathway to Mental and Physical Health
• Arketamine, a new rapid-acting antidepressant: A historical review and future directions
• Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data
• Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
• Naturalistic Psychedelic Use: A World Apart from Clinical Care
• Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
• Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
• The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
• Effective connectivity of functionally anticorrelated networks under LSD
• Acute and enduring effects of naturalistic psychedelic use among Indigenous peoples in Canada and the United States
• Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
• A Dose of Creativity: An Integrative Review of the Effects of Serotonergic Psychedelics on Creativity
• Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology
• Dual action of ketamine confines addiction liability
• Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review
• The influence of ceremonial settings on mystical and challenging experiences occasioned by ayahuasca: A survey among ritualistic and religious ayahuasca users
• Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey
• Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape
• Pattern Breaking: A Complex Systems Approach to Psychedelic Medicine
• The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
• Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects
• Opening to Awe: Psychedelic-Assisted Self-Transcendence and Positive Adult Development
• CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity
• At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial
• From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)
• Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
• Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study
• Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees
• Brain dynamics predictive of response to psilocybin for treatment-resistant depression
• A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
• Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression
• Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
• Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
• Belief changes associated with psychedelic use
• Neuroimaging in psychedelic drug development: Past, present, and future
• Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior
• Participation in an indigenous Amazonian led ayahuasca retreat associated with increases in nature relatedness – a pilot study
• Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies
• Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico
• Associations between classic psychedelics and nicotine dependence in a nationally representative sample
• Sustained effects of single doses of classical psychedelics in humans
• MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial
• Dose-related Behavioral, Subjective, Endocrine and Psychophysiological Effects Of the Kappa Opioid Agonist Salvinorin A in Humans
• Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
• Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate
• Nootropic effects of LSD: Behavioral, molecular and computational evidence
• MDMA for the Treatment of Negative Symptoms in Schizophrenia
• Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
• Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
• Motives for the use of serotonergic psychedelics: A systematic review
• Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study
• A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population
• Don’t Be Afraid, Try to Meditate- Potential Effects on Neural Activity and Connectivity of Psilocybin-Assisted Mindfulness-Based Intervention for Social Anxiety Disorder: A systematic review
• Language Models Learn Sentiment and Substance from 11,000 Psychoactive Experiences
• Self-Actualization and the Integration of Psychedelic Experience: The Mediating Role of Perceived Benefits to Narrative Self-Functioning
• Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
• Application of machine learning and complex network measures to an EEG dataset from ayahuasca experiments
• The Acute Effects of Psychoactive Drugs on Emotional Episodic Memory Encoding, Consolidation, and Retrieval
• Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model
• Postpartum depression: A role for psychedelics?
• 5-HT2CR Is as Important as 5-HT2AR in Inducing Hallucinogenic Effects in Serotonergic Compounds
• Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics
• Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)
• Ayahuasca and Public Health II: Health Status in a Large Sample of Ayahuasca-Ceremony Participants in the Netherlands
• Psychedelic Therapy for Body Dysmorphic Disorder
• Unique Effects of Sedatives, Dissociatives, Psychedelics, Stimulants, and Cannabinoids on Episodic Memory: A Review and Reanalysis of Acute Drug Effects on Recollection, Familiarity, and Metamemory
• Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default
• New insights into the clinical and nonclinical effects of psychedelic substances: An integrative review
• The role of extracellular serotonin and MDMA in the sensitizing effects of MDMA
• Incilius alvarius cell-based synthesis of 5-MeO-DMT
• The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences
• Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation
• Traditional Amazonian medicine in addiction treatment: Qualitative results
• Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity
• Psychedelic Resting-state Neuroimaging: A Review and Perspective on Balancing Replication and Novel Analyses
• Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results
• Psychedelics as potential catalysts of scientific creativity and insight
• Self-Care Practices with Psychedelics – A Qualitative Study of Users’ Perspectives
• Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations
• Pharmacokinetics of N,N-dimethyltryptamine in Humans
• Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis
• Lay Perceptions of Treating Mental Illness with Psychedelic Assisted Therapy
• Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature
• Socio-psychedelic imaginaries: envisioning and building legal psychedelic worlds in the United States
• Characterizing thalamocortical (dys)connectivity following d-amphetamine, LSD, and MDMA administration
• Phenomenology and Content of the Inhaled N, N-Dimethyltryptamine (N, N-DMT) Experience
• Past-Year Hallucinogen Use in Relation to Psychological Distress, Depression, and Suicidality among US Adults
• Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences
• The Effects of Psilocybin in Adults with Major Depressive Disorder and The General Population
• Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex
• Differences in personality, cognitive abilities, illicit drug use, and white matter structural integrity between hallucinogen users and matched controls
• Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
• New Insights into the Chemical Composition of Ayahuasca
• Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders
• Ketamine for suicidality: an umbrella review
• Prospective association of psychological pain and hopelessness with suicidal thoughts
• Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder
• Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention and treatment
• Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms
• Effects of classic psychedelic drugs on turbulent signatures in brain dynamics
• Increased global integration in the brain after psilocybin therapy for depression
• Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample
• Insights for the Use of Ketamine From Randomized Controlled Trials That Compared Ketamine With Electroconvulsive Therapy in Severe Depression
• Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
• Integration in Psychedelic-Assisted Treatments: Recurring Themes in Current Providers’ Definitions, Challenges, and Concerns
• Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience
• A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities
• Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD
• Psilocybin-Assisted Compassion Focused Therapy for Depression
• Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated
• Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences
• Predictors and potentiators of psychedelic-occasioned mystical experiences
• Asymmetry in Psychoactive Research: A Bibliometric Study on 15 Psychoactive Drugs
• Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada
• How Low-Doses Of Psychedelics Compliment High Dose Experiences: Observational Evidence In Naturalistic Settings
• Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behaviour, cortical synaptogenesis deficits and serotonergic neurotransmission decline
• Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs
• Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design
• Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial
• Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression
• Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study
• Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States
• Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
• Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network
• Disintegrating and Reintegrating the Self – (In)Flexible Self-Models in Depersonalisation and Psychedelic Experiences
• A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis
• Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report
• Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro
• Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
• Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca
• Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study
• Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers
• MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD
• Role of 5-HT2A receptors in the effects of ayahuasca on ethanol self-administration using a two-bottle choice paradigm in male mice
• How Psychedelic-Assisted Treatment Works in the Bayesian Brain
• Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study
• Micro-dosing psychedelics as a plausible adjunct to psychosexual and couple’s therapy: a qualitative insight
• Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
• Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees
• Psilocybin induces spatially constrained alterations in thalamic functional organization and connectivity
• The challenges ahead for psychedelic ‘medicine’
• The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study
• Kratom Abuse Potential 2021: An Updated Eight Factor Analysis
• Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
• Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
• Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil
• MDMA and memory, addiction, and depression: dose-effect analysis
• Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression
• The Effects of Drugs on Behavior Maintained by Social Contact: Role of Monoamines in Social Reinforcement
• Natural language signatures of psilocybin microdosing
• Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing
• Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study
• Increased low-frequency brain responses to music after psilocybin therapy for depression
• Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction
• Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
• A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults
• Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
• The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
• The Effects of MDMA-Assisted Therapy on Alcohol and Substance Use in a Phase 3 Trial for Treatment of Severe PTSD
• LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility
• Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users
• Microdosing as a Response to the Meaning Crisis: A Qualitative Analysis
• Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy
• Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature
• Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines
• MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial
• Ketamine as an adjunctive therapy for major depression – a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
• Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study
• Psilocybin in long-term meditators: Effects on default mode network functional connectivity and retrospective ratings of qualitative experience
• Couple Therapy with MDMA – Proposed Pathways of Action
• Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans
• Response to Intravenous Racemic Ketamine After Switch From Intranasal (S)-ketamine on Symptoms of Treatment-Resistant Depression and PTSD in Veterans: a Retrospective Case Series
• Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy
• Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
• Repeated low doses of LSD in healthy adults: A placebo-controlled, dose–response study
• Structure-based discovery of nonhallucinogenic psychedelic analogs
• LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking
• Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension
• Psychedelic Group Therapy
• Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure
• The frontiers of new psychedelic therapies: A survey of sociological themes and issues
• Classic Psychedelic Drugs: Update on Biological Mechanisms
• Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder
• Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?
• Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study
• Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychotic Symptoms
• Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants
• Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Women
• Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
• Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
• Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
• Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation
• Decreases in Suicidality Following Psychedelic Therapy: A Meta-Analysis of Individual Patient Data Across Clinical Trials
• Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active-duty military: a double-blind, randomized, placebo-controlled multi-centre clinical trial
• A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
• The relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression
• Evenings with Molly: Adult Couples’ Use of MDMA for Relationship Enhancement
• Oral ketamine reduces the experience of stress in people with chronic suicidality
• Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder
• The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Classical Psychedelics
• Dynamic reconfiguration of frequency-specific cortical coactivation patterns during psychedelic and anaesthetized states induced by ketamine
• Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
• Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States
• The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of its Provision
• Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression
• MDMA related neuroinflammation and adenosine receptors
• Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
• MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults
• Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes
• Overcoming epistemic injustices in the biomedical study of ayahuasca: Towards ethical and sustainable regulation
• The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation
• Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
• Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression
• A systematic literature review of clinical trials and therapeutic applications of ibogaine
• A retrospective analysis of the “Neverending Trip” after administration of a potent full agonist of 5-HT2A receptor – 25I-NBOMe
• Effective Connectivity of LSD-induced Ego Dissolution
• Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
• A network model of the modulation of gamma oscillations by NMDA receptors in cerebral cortex
• Nitrous Oxide: an emerging novel treatment for treatment-resistant depression
• Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects
• Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples
• Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies
• Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders
• Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA
• Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study
• Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review
• Reduced precision underwrites ego dissolution and therapeutic outcomes under psychedelics
• Psychedelic Therapy’s Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
• Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA
• Beating Pain with Psychedelics: Matter over Mind?
• Self-Administration of Entactogen Psychostimulants Dysregulates Gamma-Aminobutyric Acid (GABA) and Kappa Opioid Receptor Signaling in the Central Nucleus of the Amygdala of Female Wistar Rats
• Receptor interaction profiles of 4-alkoxy-3,5-dimethoxyphenethylamines (mescaline derivatives) and related amphetamines
• Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression
• Psilocybin therapy of psychiatric disorders is not hampered by hERG potassium channel-mediated cardiotoxicity
• Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects
• The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955 – 2021)
• Hallucinogens, Serotonin and Obsessive-Compulsive Disorder
• Models of psychedelic drug action: modulation of cortical-subcortical circuits
• Toward a positive psychology of psychoactive drug use
• Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency
• Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the Canadian rapid treatment center of excellence
• Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity
• A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development
• Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
• No evidence that LSD microdosing affects recall or the balance between distracter resistance and updating
• Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial
• Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials
• Epidemiology of hospitalizations with hallucinogen use disorder: a 17-year U.S. National study
• Pharmacogenomics of ketamine: A systematic review
• Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology
• Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
• Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors
• Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial
• Recreational Psychedelic Users Frequently Encounter Complete Mystical Experiences: Trip Content and Implications for Wellbeing
• Psychedelic-Inspired Approaches for Treating Neurodegenerative Disorders
• Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review
• A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in healthy volunteers
• The readiness of psychiatrists to implement psychedelic-assisted psychotherapy
• Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality
• Psychedelics as Tools for Belief Transmission. Set, Setting, Suggestibility, and Persuasion in the Ritual Use of Hallucinogens
• A Semantic Scale Network analysis of the revised Mystical Experiences Questionnaire: A call for collaboration
• Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans
• Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
• Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism
• Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
• Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression
• Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
• Human behavioral pharmacology of psychedelics
• Natural Language as a Window into the Subjective Effects and Neurochemistry of Psychedelic Drugs
• Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
• Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects
• Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
• Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead
• Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation
• Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice
• The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality
• Efficacy of ketamine in the treatment of migraines and other unspecified primary headache disorders compared to placebo and other interventions: a systematic review
• Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
• Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow
• The Power of Social Attribution: Perspectives on the Healing Efficacy of Ayahuasca
• MDMA-assisted psychotherapy for treatment of post-traumatic stress disorder: a systematic review with meta-analysis
• Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
• Patents on Psychedelics: The Next Legal Battlefront of Drug Development
• Does ±3,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis
• Psilocybin Newspaper Coverage – Sentiment and Frequency (1989-2020)
• The moderating role of mystical-type experiences on the relationship between existential isolation and meaning in life
• A narrative synthesis of research with 5-MeO-DMT
• Why was early therapeutic research on psychedelic drugs abandoned?
• Can Quetiapine Prolong the Antidepressant Effect of Ketamine?: A 5-Year Follow-up Study
• Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality
• Communalistic use of psychoactive plants as a bridge between traditional healing practices and Western medicine: A new path for the Global Mental Health movement
• Family of Structurally Related Bioconjugates Yields Antibodies with Differential Selectivity against Ketamine and 6-Hydroxynorketamine
• Increased sensitivity to strong perturbations in a whole-brain model of LSD
• Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States
• Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders
• Serotonergic Psychedelics in Neural Plasticity
• Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis
• Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample
• Neurological and cognitive alterations induced by MDMA in humans
• Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults
• Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research
• Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity
• Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study
• Relationships between reduction in symptoms and restoration of function and wellbeing: Outcomes of the Oral Ketamine Trial on Suicidality (OKTOS)
• Self-reported PTSD is associated with increased use of MDMA in adolescents with substance use disorders
• MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder
• Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science
• “This Is Something That Changed My Life”: A Qualitative Study of Patients’ Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders
• Ayahuasca, a psychedelic beverage, modulates neuroplasticity induced by ethanol in mice
• Ayahuasca Lyophilization (Freeze-drying) Protocol with Pre- and Post-procedure Alkaloids Quantification
• Psychedelics use predicts more positive emotional reactivity and greater self-awareness: the mediating role of ego dissolution and mystical experiences
• Consciousness in active inference: Deep self-models, other minds, and the challenge of psychedelic-induced ego-dissolution
• Psychedelic mushrooms in the USA: Knowledge, patterns of use and association with health outcomes
• Prefrontal contributions to the stability and variability of thought and conscious experience
• The kappa opioid receptor and the sleep of reason: Cortico-subcortical imbalance following salvinorin-A
• Ibogaine Blocks Cue- and Drug-Induced Reinstatement of Conditioned Place Preference to Ethanol in Male Mice
• Discovery of G Protein-Biased Antagonists against 5-HT7R
• Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being
• Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis
• Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
• A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing
• Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
• LSD degrades hippocampal spatial representations and suppresses hippocampal-visual cortical interactions
• Spiritual experiences in psychedelic-assisted psychotherapy: Case reports of communion with the divine, the departed, and saints in research using psilocybin for the treatment of alcohol dependence
• Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis
• On Revelations and Revolutions: Drinking Ayahuasca Among Palestinians Under Israeli Occupation
• Safety pharmacology of acute LSD administration in healthy subjects
• From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders
• Do Psychedelics Change Beliefs?
• On Perception and Consciousness in HPPD: A Systematic Review
• “Meeting the Medicine Halfway”: Ayahuasca Ceremony Leaders’ Perspectives on Preparation and Integration Practices for Participants
• LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1
• Psychedelics, sociality, and human evolution
• The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies
• Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States
• Sub-acute and long-term effects of ayahuasca on mental health and well-being in healthy ceremony attendants: A replication study
• Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
• In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept
• Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression
• Ayahuasca may help to improve self-compassion and self-criticism capacities
• The iboga alkaloids
• Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey
• Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
• The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020)
• Recreation and Realization: Reported Motivations of Use Among Persons Who Consume Psychedelics in Non-Clinical Settings
• Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color
• On the Varieties of Conscious Experiences: Altered Beliefs Under Psychedelics (ALBUS)
• Cancer Healthcare Workers’ Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation
• A draft reference assembly of the Psilocybe cubensis genome
• Two Models of Legalization of Psychedelic Substances: Reasons for Concern
• Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence
• Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics
• Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs
• Turn on, Tune in, and Drop out: Predictors of Attrition in a Prospective Observational Cohort Study on Psychedelic Use
• Psychedelic medicine: a re-emerging therapeutic paradigm
• Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens
• A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats
• Safer Tripping: Serotonergic Psychedelics and Drug Checking. Submission and Detection Rates, Potential Harms, and Challenges for Drug Analysis
• Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international cross-sectional survey
• A Nationwide Study Comparing Mental Health Professionals’ Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice
• Trips and Neurotransmitters: Discovering Principled Patterns across 6,850 Hallucinogenic Experiences
• Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
• Ketamine accelerates fear extinction via mTORC1 signaling
• Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use
• Psychedelic drug use and schizotypy in young adults
• Psychedelics not linked to mental health problems or suicidal behavior: A population study
• Lysergide Treatment of Schizophrenic and Nonschizophrenic Alcoholics; A Controlled Evaluation
• Phenomenology, Structure, and Dynamic of Psychedelic States
• Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review
• Prophylactic Ketamine Attenuates Learned Fear
• Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature
• Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects
• Possible role of biochemiluminescent photons for lysergic acid diethylamide (LSD)-induced phosphenes and visual hallucinations
• Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies
• The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder
• Effects of ayahuasca on personality: results of two randomized, placebo-controlled trials in healthy volunteers
• Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy
• A dynamic and multilocus metabolic regulation strategy using quorum-sensing-controlled bacterial small RNA
• The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors
• Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review
• Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome
• MDMA does not alter responses to the Trier Social Stress Test in humans
• Pharmacological fMRI: Effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network
• Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK
• Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches
• Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF)
• A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial
• Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment
• Working with Weirdness: A Response to “Moving Past Mysticism in Psychedelic Science”
• Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson’s Disease?
• Acute Biphasic Effects of Ayahuasca
• Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders
• Dynamic coupling of whole-brain neuronal and neurotransmitter systems
• Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
• MDMA, cannabis, and cocaine produce acute dissociative symptoms
• Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
• Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or ‘ecstasy’ and self-focused compassion: Preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices
• Sex differences and serotonergic mechanisms in the behavioural effects of psilocin
• Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
• Naturalistic Entheogenics: Précis of Philosophy of Psychedelics
• Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions
• Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats
• Psilocybin and LSD Have No Long-Lasting Effects in an Animal Model of Alcohol Relapse
• Associations between lifetime classic psychedelic use and cardiometabolic diseases
• Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution
• Modulation of Social Cognition via Hallucinogens and “Entactogens”
• Psychedelic use and intimate partner violence
• Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects
• Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
• Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects
• Self-reported negative outcomes of psilocybin users: A quantitative textual analysis
• MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t
• Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics
• Psychedelics and hypnosis: Commonalities and therapeutic implications
• New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity
• In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation
• Greater empathy in MDMA users
• Four weekly ayahuasca sessions lead to increases in “acceptance” capacities: a comparison study with a standard 8-week mindfulness training program
• Serotonin toxicity of serotonergic psychedelics
• LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model
• Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study
• Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD
• The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial
• Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
• High dose psilocybin is associated with positive subjective effects in healthy volunteers
• Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness
• Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
• Potential Use of Ayahuasca in Grief Therapy
• Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression
• Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?
• Harmine produces antidepressant-like effects via restoration of astrocytic functions
• A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
• Ayahuasca and Its DMT- and β-carbolines – Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment
• Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT
• Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review
• Case Report: Ketamine for Pain and Depression in Advanced Cancer
• Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
• Dreams and psychedelics: neurophenomenological comparison and therapeutic implications
• Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes
• Effect of psilocybin on empathy and moral decision-making
• Determination of Tryptamines and β-Carbolines in Ayahuasca Beverage Consumed During Brazilian Religious Ceremonies
• Pharmacokinetics and concentration-effect relationship of oral LSD in humans
• Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression
• Psychedelic Psychiatry’s Brave New World
• Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
• Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders
• Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report
• Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial
• The prosocial effects of 3, 4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals
• Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
• Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations
• LSD-associated “Alice in Wonderland Syndrome”(AIWS): A Hallucinogen Persisting Perception Disorder (HPPD) Case Report
• Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada
• Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
• Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement
• 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning
• The chemical induction of synaesthesia
• Psychedelics for Brain Injury: A Mini-Review
• Increased Entropic Brain Dynamics during DeepDream-Induced Altered Perceptual Phenomenology
• Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice
• Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review
• Genie in a blotter: A comparative study of LSD and LSD analogues’ effects and user profile
• Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
• Relational and Growth Outcomes Following Couples Therapy With MDMA for PTSD
• Role of the 5-HT2A receptor in acute effects of LSD on empathy and circulating oxytocin
• Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
• R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
• Noribogaine is a G-Protein Biased κ-Opioid Receptor Agonist
• Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
• Psychedelics alter metaphysical beliefs
• Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
• Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial
• Psychedelics and virtual reality: parallels and applications
• Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use
• Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research
• How Religion, Race, and the Weedy Agency of Plants Shape Amazonian Home Gardens
• Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users
• Subacute Effects of the Psychedelic Ayahuasca on the Salience and Default Mode Networks
• Oxytocin-dependent reopening of a social reward learning critical period with MDMA
• LSD induces increased signalling entropy in rats’ prefrontal cortex
• Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.
• A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens
• Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects
• Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA
• Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration
• Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA)
• Natural Psychoplastogens As Antidepressant Agents
• Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
• Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study
• Microdosing Psychedelics as a Promising New Pharmacotherapeutic
• Predictive feedback, early sensory representations and fast responses to predicted stimuli depend on NMDA receptors
• Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
• Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
• The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
• Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
• Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use
• Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport
• Long-Term Efficacy of Combination Therapy of Transcranial Magnetic Stimulation with Ketamine for Patients with Treatment-Resistant Depression
• Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature
• Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics
• Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter
• Psilocybin and MDMA for the treatment of trauma-related psychopathology
• Ketamine Modulates the Neural Correlates of Reward Processing in Unmedicated Patients in Remission from Depression
• Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis
• Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties
• Effects of Acute Drug Administration on Emotion: a Review of Pharmacological MRI Studies
• Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
• Ketamine for Refractory Chronic Migraine: an Observational Pilot Study and Metabolite Analysis
• Narrative identity, rationality, and microdosing classic psychedelics
• Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects
• Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression
• Effects of MDMA on attention to positive social cues and pleasantness of affective touch
• Hemorheological and metabolic consequences of renal ischemia-reperfusion and their modulation by N,N-dimethyl-tryptamine on a rat model
• Interaction of Sex and Age on the Dissociative Effects of Ketamine Action in Young Healthy Participants
• Metabolism of lysergic acid diethylamide (LSD): an update
• Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
• High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans.
• Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report
• The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens
• Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration
• Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence
• Collective self-experimentation in patient-led research: How online health communities foster innovation
• Metabolite Profiling of Antiaddictive Alkaloids from Four Mexican Tabernaemontana Species and the Entheogenic African Shrub Tabernanthe iboga (Apocynaceae)
• Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study
• Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial
• Acute effects of ayahuasca in a juvenile non-human primate model of depression
• Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants
• Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats
• Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder
• Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example
• Chronic, Intermittent Microdoses of the Psychedelic N, N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents
• Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action
• Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.
• Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
• Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis
• Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers
• Motives and side-effects of microdosing with psychedelics among users
• Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder
• A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
• Psychedelic medicalization, public discourse, and the morality of ego dissolution
• Neuroimaging of chronic MDMA (“ecstasy”) effects: A meta-analysis
• An Encounter with the Other: A Thematic Analysis of Accounts of DMT Experiences from a Naturalistic Field Study
• Long-lasting analgesic effect of the psychedelic drug changa: A case report
• ‘Never drop without your significant other, cause that way lies ruin’: The boundary work of couples who use MDMA together
• Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses
• Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study
• Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the hippocampus of rats
• A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics
• Chemistry and Structure-Activity Relationships of Psychedelics
• Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness
• Reconciling Mystical Experiences with Naturalistic Psychedelic Science: Reply to Sanders and Zijlmans
• Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans: Preliminary Evidence of Interactive Effects of Ayahuasca and Endocannabinoids in a Healthy Human Subject
• Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression
• The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder
• Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives
• Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain
• Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
• Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
• Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial
• Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution
• Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies
• Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment
• Effect of Ritualistic Consumption of Ayahuasca on Hepatic Function in Chronic Users
• Increased use of illicit drugs in a Dutch cluster headache population
• Disentangling the association of depression on the anti-fatigue effects of ketamine
• The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study
• N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain
• Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile
• Subjective effects of MDMA (‘Ecstasy’) on human sexual function
• MDMA and Human Sexual Function
• Low-dose ketamine does not improve the speed of recovery from depression in electroconvulsive therapy: a randomized controlled trial
• MDMA and Sexual Behavior: Ecstasy Users’ Perceptions About Sexuality and Sexual Risk
• Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults
• Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample
• Does psychedelic therapy have a transdiagnostic action and prophylactic potential?
• Psychedelic Medicines in Major Depression: Progress and Future Challenges
• Day trip to hell: A mixed methods study of challenging psychedelic experiences
• Psychedelics and health behaviour change
• Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress
• Dark Classics in Chemical Neuroscience: Mescaline
• Psychedelic-Assisted Group Therapy: A Systematic Review
• The socialization of hallucinations. Cultural priors, social interactions and contextual factors in the use of psychedelics
• Catalysts for change: the cellular neurobiology of psychedelics
• Visitors of the Dutch drug checking services: Profile and drug use experience
• Registered clinical studies investigating psychedelic drugs for psychiatric disorders
• Practices in search of legitimacy. The contemporary use of ayahuasca, between religious and therapeutic vindications
• Low-dose ketamine for treatment resistant depression in an academic clinical practice setting
• Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: A transcultural study
• An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress
• Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic
• Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety
• The antiaddictive effects of ibogaine: A systematic literature review of human studies
• Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder
• Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
• Sex differences in sub-anesthetic ketamine’s antidepressant effects and abuse liability
• Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination
• Harmines inhibit cancer cell growth through coordinated activation of apoptosis and inhibition of autophagy
• Psychedelics as anti-inflammatory agents
• A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience
• Improving cognitive functioning in major depressive disorder with psychedelics: a dimensional approach
• Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
• Key interindividual determinants in MDMA pharmacodynamics
• Influence of Environmental Factors and Cultural Methods on the Content of N,N‑Dimethyltryptamine in Psychotria viridis (Rubiaceae)
• Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats
• Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach
• A Single Dose Of Ayahuasca Modulates Salivary Cortisol In Treatment-Resistant Depression
• Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
• A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus
• Harmine stimulates proliferation of human neural progenitors
• Are Ecstasy Induced Serotonergic Alterations Overestimated For The Majority Of Users?
• Salvinorin A preserves cerebral pial artery autoregulation after forebrain ischemia via the PI3K/AKT/cGMP pathway
• Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
• A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification
• Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)
• Rapid antidepressant effect of S-ketamine in schizophrenia
• Ketamine normalizes brain activity during emotionally valenced attentional processing in depression
• Production Options for Psilocybin: Making of the Magic
• Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
• Decreased brain modularity after psilocybin therapy for depression
• Self-Experiments with Psychoactive Substances: A Historical Perspective
• Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
• Effects of ketamine, dexmedetomidine and propofol anesthesia on emotional memory consolidation in rats: Consequences for the development of post-traumatic stress disorder
• Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions
• Acute pharmacological effects of 2C-B in humans: An observational study
• Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile
• Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine
• Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
• Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study
• Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
• Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
• Powerful substances in tiny amounts An interview study of psychedelic microdosing
• Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center
• Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
• Ketamine anesthesia enhances fear memory consolidation via noradrenergic activation in the basolateral amygdala
• MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor
• Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
• Effective connectivity changes in LSD-induced altered states of consciousness in humans
• Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organisation under LSD
• Increased Activation of Indirect Semantic Associations under Psilocybin
• Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
• Psychedelic microdosing benefits and challenges: an empirical codebook
• Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness
• (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function
• LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark
• The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice
• Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability
• Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues
• Ibogaine: a review
• Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases
• Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?
• Blood d-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine
• Potential applications for sigma receptor ligands in cancer diagnosis and therapy
• Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
• The Use of Salvia divinorum from a Mazatec Perspective
• Ketamine administration in depressive disorders: a systematic review and meta-analysis
• The role of ketamine in treatment-resistant depression: a systematic review
• The need for publicly funded research on therapeutic use of psychedelic drugs
• From hallucinations to synaesthesia: a circular inference account of unimodal and multimodal erroneous percepts in clinical and drug-induced psychosis
• A window into the intoxicated mind? Speech as an index of psychoactive drug effects
• Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells
• Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers: results of an experimental double-blind placebo-controlled study
• Effects of ecstasy on cooperative behaviour and perception of trustworthiness: A naturalistic study
• Acute LSD effects on response inhibition neural networks
• Side-effects associated with ketamine use in depression: a systematic review
• MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent ‘Ecstasy’ users
• Migraine prevalence in visual snow with prior illicit drug use (Hallucinogen Persisting Perception Disorder) versus without
• Investigation of the Structure−Activity Relationships of Psilocybin Analogues
• Discriminative Stimulus Effects of Substituted Tryptamines in Rats
• Changes in self-rumination and self-compassion mediate the effect of psychedelic experiences on decreases in depression, anxiety, and stress
• MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections
• LSD flattens the brain′s energy landscape: evidence from receptor-informed network control theory
• The Shipibo Ceremonial Use of Ayahuasca to Promote Well-Being: An Observational Study
• Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?
• New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
• Drug models of schizophrenia
• Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
• Lysergic acid diethylamide: side effects and complications
• The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
• Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial
• Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
• Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches
• MDA, MDMA and other mescaline-like substances in the US military’s search for a truth drug (1940s to 1960s)
• Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017
• Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers
• Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial
• Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
• Why MDMA therapy for alcohol use disorder? And why now?
• A single infusion of ketamine improves depression scores in patients with anxious bipolar depression
• Ketamine and other potential glutamate antidepressants
• Psilocybin and obsessive compulsive disorder
• Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety
• Ketamine Use for Suicidal Ideation in the General Hospital: Case Report and Short Review
• The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson’s disease
• Inhibitory effects of ibogaine on cocaine self-administration in rats
• Nitrous Oxide for Treatment-Resistant Major Depression: a Proof-of-Concept Trial
• Crisis Intervention Related to the Use of Psychoactive Substances in Recreational Settings – Evaluating the Kosmicare Project at Boom Festival
• Toxicities Associated With NBOMe Ingestion—A Novel Class of Potent Hallucinogens: A Review of the Literature
• Immunological Effects of Ayahuasca in Humans
• N,N-dimethyltryptamine and the pineal gland: Separating fact from myth
• Psychedelic pleasures: An affective understanding of the joys of tripping
• Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling
• Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes
• Dimensions of consciousness and the psychedelic state
• Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor
• Restructuring consciousness -the psychedelic state in light of integrated information theory
• First Time View on Human Metabolome Changes after a Single Intake of 3,4-Methylenedioxymethamphetamine in Healthy Placebo-Controlled Subjects
• Psychedelic Drugs in Biomedicine
• Therapeutic Potential Ascribed to Ayahuasca by Users in the Czech Republic
• Single Ketamine Infusion and Neurocognitive Performance in Bipolar Depression
• Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
• Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics
• Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression
• Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia
• Relational Processes in Ayahuasca Groups of Palestinians and Israelis
• Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities
• Therapeutic potential of ketamine for alcohol use disorder
• Developing Guidelines and Competencies for the Training of Psychedelic Therapists
• Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)
• The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
• Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports
• Do NMDA-R Antagonists Re-Create Patterns of Spontaneous Gamma-Band Activity in Schizophrenia? A Systematic Review and Perspective
• A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers
• Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice
• The relationships of classic psychedelic use with criminal behavior in the United States adult population
• Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
• Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy
• The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors
• Acute effects of methylphenidate, modafinil and MDMA on negative emotion processing
• Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine
• Regulation of human research with LSD in the United States (1949-1987)
• Ketamine’s antidepressant effect is mediated by energy metabolism and antioxidant defense system
• Psychedelic drug assisted psychotherapy in patients with terminal cancer
• Pahnke’s ‘Good Friday Experiment’: a long-term follow-up and methodological critique
• The anterior cingulate cortex as a key locus of ketamine’s antidepressant action
• Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy
• Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia
• The entropic tongue: Disorganization of natural language under LSD
• Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features
• The Effects of Hallucinogens on Gene Expression
• A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
• Self unbound: ego dissolution in psychedelic experience
• A Physician’s Attempt to Self-Medicate Bipolar Depression with N,N-Dimethyltryptamine (DMT)
• Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
• Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities
• LSD experiments by the United States Army
• Effects of Long-Term Ayahuasca Administration on Memory and Anxiety in Rats
• Low-dose ketamine for treatment resistant depression in an academic clinical practice setting
• Neuroimaging in moderate MDMA use: A systematic review
• The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro
• Mushroom-Derived Indole Alkaloids
• MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
• A continuum hypothesis of psychotomimetic rapid antidepressants
• Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic
• Acute and subacute psychoactive effects of Kambô, the secretion of the Amazonian Giant Maki Frog (Phyllomedusa bicolor): retrospective reports
• Moving Past Mysticism in Psychedelic Science
• Set and Setting in the Santo Daime
• Making a medicine out of MDMA
• The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
• Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
• Psychological and cognitive effects of long-term peyote use among Native Americans
• Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography
• The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
• Neurotoxicity and LSD treatment: a follow-up study of 151 patients in Denmark
• Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers
• Haoma-Soma in the world of ancient Greece
• Wasson’s alternative candidates for soma
• Beringian origins and cryptic speciation events in the fly agaric (Amanita muscaria)
• Amanita muscaria: chemistry, biology, toxicology, and ethnomycology
• Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects
• When the endogenous hallucinogenic trace amine N, N-dimethyltryptamine meets the sigma-1 receptor
• Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca
• The pharmacology of psilocybin
• Report on psychoactive drug use among adolescents using ayahuasca within a religious context
• How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale
• Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease
• The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series
• Pyretogenic effect of lysergic acid diethylamide
• The persistence of the subjective in neuropsychopharmacology: observations of contemporary hallucinogen research
• Ayahuasca Beyond the Amazon: the Benefits and Risks of a Spreading Tradition
• Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model
• The psychology of philosophy: Associating philosophical views with psychological traits in professional philosophers
• Recreational Use, Analysis and Toxicity of Tryptamines
• Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder
• Challenges in translational research: MDMA in the laboratory versus therapeutic settings
• Ketamine safety and tolerability in clinical trials for treatment-resistant depression
• Distinct trajectories of antidepressant response to intravenous ketamine
• Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies
• Ketamine for bipolar depression: a systematic review
• Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study
• Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes
• Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials
• Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistance Depression and Major Depression with Suicide Ideation: A Meta-Analysis
• Psychedelic-inspired drug discovery using an engineered biosensor
• Psycho-Mycological Studies Of Amanita – From Ancient Sacrament To Modern Phobia
• Amanita muscaria (fly agaric): from a shamanistic hallucinogen to the search for acetylcholine
• Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
• Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey
• A Qualitative Study of Intention and Impact of Ayahuasca Use by Westerners
• Clinical Studies of Lysergic Acid Diethylamide
• Experiences of Encounters with Ayahuasca – “the Vine of the Soul”
• Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverages
• Effects of mescaline and lysergic acid (d-LSD-25)
• Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects
• Convergent Mechanisms Underlying Rapid Antidepressant Action
• A Systematic Review of the MDMA Model to Address Social Impairment in Autism
• Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers
• Anti-inflammatory activity of ayahuasca and its implications for the treatment of neurological and psychiatric diseases
• Changes in Spirituality Among Ayahuasca Ceremony Novice Participants
• Mental changes experimentally produced by d-lysergic acid diethylamide tartrate
• Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
• Symptom specificity of ayahuasca’s effect on depressive symptoms
• Effects of varied doses of psilocybin on time interval reproduction in human subjects
• Cannabis and Ecstasy/MDMA: Empirical measures of creativity in recreational users
• A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
• Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin
• Composition, Standardization and Chemical Profiling of Banisteriopsis caapi, a Plant for the Treatment of Neurodegenerative Disorders Relevant to Parkinson’s Disease
• Response of cluster headache to psilocybin and LSD
• Unauthorized Research on Cluster Headache
• Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial
• Reflections on the Concord Prison Project and the follow-up study
• Serotonin research: contributions to understanding psychoses
• Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness
• Psychonauts’ psychedelics: A systematic, multilingual, web-crawling exercise
• The psychedelic mystical experience in the human encounter with death
• Treating drug dependence with the aid of ibogaine: A retrospective study
• The Phenomenology and Potential Religious Import of States of Consciousness Facilitated by Psilocybin
• A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial
• The pharmacology of lysergic acid diethylamide: a review
• The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval
• Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively
• Ketamine For Post-Traumatic Stress Disorders And Its Possible Therapeutic Mechanism
• Plasma BDNF concentrations and the antidepressant effects of six ketamine infusions in unipolar and bipolar depression
• Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
• Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking
• Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland
• Ethics and ego dissolution: the case of psilocybin
• Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
• Ayahuasca and Spiritual Crisis: Liminality as Space for Personal Growth
• The correlation between ketamine and posttraumatic stress disorder in burned service members
• Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
• Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex
• Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms
• Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans
• Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus
• Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile
• EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat
• Structure–Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore
• Psilocybin in end of life care: Implications for further research
• Serotonergic Hallucinogen-Induced Visual Perceptual Alterations
• A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties
• The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?
• Serotonin antagonists fail to alter MDMA self-administration in rats
• 5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?
• Crystal Structure of an LSD-Bound Human Serotonin Receptor
• The fibrinolytic system: A new target for treatment of depression with psychedelics
• Administration of ketamine for unipolar and bipolar depression
• The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells
• A Public-Health-Based Vision for the Management and Regulation of Psychedelics
• MDMA and PTSD treatment: “PTSD: from novel pathophysiology to innovative therapeutics”
• Clinical Applications of Hallucinogens: A Review
• A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience
• The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
• Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans
• Cardiac arrest after ibogaine intoxication
• Medicine, religion and ayahuasca in Catalonia. Considering ayahuasca networks from a medical anthropology perspective
• Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression
• Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression
• The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization
• Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients
• Creativity and Psychoactive Substance Use: A Systematic Review
• Treatment of acute opioid withdrawal with ibogaine
• Effects of low dose ibogaine on subjective mood state and psychological performance
• Intravenous arketamine for treatment-resistant depression: open-label pilot study
• MDMA and the “Ecstasy Paradigm”
• Psychedelic science in post-COVID-19 psychiatry
• Trial of Psilocybin versus Escitalopram for Depression
• Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
• Experimental Psychiatry. V — Psilocybine, a New Psychotogenic Drug
• Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics
• Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits
• The Promise of Psychedelic Science
• Ethical Concerns about Psilocybin Intellectual Property
• Ethical and legal issues in psychedelic harm reduction and integration therapy
• Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder
• Spontaneous and deliberate creative cognition during and after psilocybin exposure
• Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies
• History and Future of the Multidisciplinary Association for Psychedelic Studies (MAPS)
• The History of MDMA as an Underground Drug in the United States, 1960-1979
• Autistic Schizophrenic Children: An Experiment in the Use of D-Lysergic Acid Diethyladmide (LSD-25)
• DPT as an adjunct in psychotherapy of alcoholics
• LSD-assisted psychotherapy and the human encounter with death
• Human pharmacology of mephedrone in comparison with MDMA
• Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature
• Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids
• Psychedelics and cognitive liberty: Reimagining drug policy through the prism of human rights
• Oral ketamine for the treatment of pain and treatment-resistant depression
• Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans
• A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
• Oxytocin receptor gene variation predicts subjective responses to MDMA
• Verbal memory impairment in polydrug ecstasy users: a clinical perspective
• Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects
• Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-NN-dimethyltryptamine
• Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
• The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines
• Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects
• NMDAR inhibition-independent antidepressant actions of ketamine metabolites
• LSD-induced entropic brain activity predicts subsequent personality change
• Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial
• Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents
• LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion
• Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine
• Neuregulin signaling mediates the acute and sustained antidepressant effects of subanesthetic ketamine
• The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being – An Early Review
• Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies
• Safety pharmacology of acute MDMA administration in healthy subjects
• The association of psychedelic use and opioid use disorders among illicit users in the United States
• Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder
• Indole Alkaloids from Plants as Potential Leads for Antidepressant Drugs: A Mini Review
• Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects
• Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
• Pharmacology of MDMA in humans
• A quantitative exploration of the relationships between regular yoga practice, microdosing psychedelics, wellbeing and personality variables
• Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users
• Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis
• Psychedelic treatment of functional neurological disorder: a systematic review
• Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
• Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice
• Compassionate use of psychedelics
• Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review
• Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
• Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat
• Psychedelic Psychotherapy Insights From 25 Years of Research
• Psychological and neuropsychological assessment of regular hoasca users
• The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study
• Exploring the relationship between microdosing, personality and emotional insight: A prospective study
• Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review
• LSD and ketanserin and their impact on the human autonomic nervous system
• Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies
• The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
• Glutamate and the Neural Basis of the Subjective Effects of Ketamine: A Pharmaco–Magnetic Resonance Imaging Study
• A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
• Targeting glutamate signalling in depression: progress and prospects
• Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine
• R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
• The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
• Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression
• The Efficacy of Ketamine in the Palliative Care Setting: A Comprehensive Review of the Literature
• Ketamine as treatment for post-traumatic stress disorder: a review
• Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients
• A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study
• Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: A critical review
• Efficacy and safety of ketamine in bipolar depression: A systematic review
• Ketamine Treatment and Global Brain Connectivity in Major Depression
• The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies
• Abraham Maslow’s Interest in Psychedelic Research: A Tribute
• Ibogaine for treating drug dependence. What is a safe dose?
• The effect of ketamine on preventing postpartum depression
• Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review
• Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics
• Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review
• Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial
• A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting
• Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration
• Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
• How toxic is ibogaine?
• The psychological and physiological effects of MDMA on normal volunteers
• Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
• Using the Theory of Planned Behavior to predict implementation of harm reduction strategies among MDMA/ecstasy users
• Alterations of consciousness and mystical-type experiences after acute LSD in humans
• Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
• Associations between lifetime classic psychedelic use and markers of physical health
• Antidepressant effects of ketamine in depressed patients
• Nonanesthetic Effects of Ketamine: A Review Article
• Mechanisms of ketamine action as an antidepressant
• MDMA as a Probe and Treatment for Social Behaviors
• The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors
• Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens
• Psilocybin for treating substance use disorders?
• Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine
• Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
• Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
• Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy
• Psychedelic Effects of Ketamine in Healthy Volunteers: Relationship to Steady-state Plasma Concentrations
• Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature
• The use of illicit drugs as self-medication in the treatment of cluster headache: results from an Italian online survey
• Psilocybin – Summary of knowledge and new perspectives
• Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?
• Lysergic acid diethylamide: a drug of ‘use’?
• Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
• Examining changes in personality following shamanic ceremonial use of ayahuasca
• Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
• Neural Correlates of the Shamanic State of Consciousness
• Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
• Baseline power of theta oscillations predicts mystical-type experiences induced by DMT in a natural setting
• Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials
• On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
• Of Roots and Fruits A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences
• Potential Psychiatric Uses for MDMA
• Ketamine abuse potential and use disorder
• A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats
• Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year
• The DMT and Psilocin Treatment Changes CD11b+ Activated Microglia Immunological Phenotype
• Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
• Dose–response relationships of psilocybin-induced subjective experiences in humans
• Meta-analysis of executive functioning in ecstasy/polydrug users
• Ayahuasca: pharmacology, neuroscience and therapeutic potential
• The Heffter Research Institute: Past and Hopeful Future
• Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
• Psychedelic drugs and perception: a narrative review of the first era of research
• Ketamine-induced modulation of the thalamo-cortical network in healthy volunteers as a model for schizophrenia
• Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy
• Ketamine as a promising prototype for a new generation of rapid-acting antidepressants
• Do the dissociative side effects of ketamine mediate its antidepressant effects?
• A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness
• Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies
• Underground MDMA-, LSD-and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary
• Ketamine Users Have High Rates of Psychosis and/or Depression
• Historic psychedelic drug trials and the treatment of anxiety disorders
• The use of ketamine as an antidepressant: a systematic review and meta-analysis
• The hallucinogenic world of tryptamines: an updated review
• Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder
• MDMA decreases the effects of simulated social rejection
• Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression
• 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil
• Intimate insight: MDMA changes how people talk about significant others
• A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
• Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
• Low-dose ketamine as an adjuvant for pain control in a cancer patient: a case report
• Prolonged epigenetic and synaptic plasticity alterations following single exposure to a psychedelic in mice
• Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans
• Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial
• Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use
• Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy
• Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
• Ketamine for treatment-resistant depression: recent developments and clinical applications
• Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice
• Ketamine: A Paradigm Shift for Depression Research and Treatment
• Self-blinding citizen science to explore psychedelic microdosing
• Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports
• Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
• Prosocial effects of MDMA: A measure of generosity
• Are Psychedelics Something New in Teaching Psychopharmacology?
• Mania following use of ibogaine: A case series
• A brief survey of drug use and other activities preceding mystical-religious experiences
• Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
• A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamine
• First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants
• First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder
• Ketamine for the treatment of addiction: Evidence and potential mechanisms
• Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers
• Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report
• Reviewing the ketamine model for schizophrenia
• The Potential Dangers of Using MDMA for Psychotherapy
• Flashbacks and HPPD: A Clinical-oriented Concise Review
• Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
• A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
• Self-Experimentations with Psychedelics Among Mental Health Professionals: LSD in the Former Czechoslovakia
• How MDMAs Pharmacology and Pharmacokinetics Drive Desired Effects and Harms
• Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
• Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial
• Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder
• The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD
• A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms
• Effects of ketamine on brain function during metacognition of episodic memory
• Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine’s putative anti-addictive activity
• Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens
• LSD-assisted psychotherapy in patients with terminal cancer
• Broadband Cortical Desynchronization Underlies the Human Psychedelic State
• The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas
• Cessation and reduction in alcohol consumption and misuse after psychedelic use
• Neuroticism is associated with challenging experiences with psilocybin mushrooms
• Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers
• Narratives of the mystical among users of psychedelics
• People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
• Treatment of alcoholism using psychedelic drugs: a review of the program of research
• Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial
• Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
• Ketamine: A tale of two enantiomers
• DARK Classics in Chemical Neuroscience: Salvinorin A
• Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members
• The behavioral pharmacology of hallucinogens
• Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism
• Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
• Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior
• From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethlyamide
• Ayahuasca and cancer treatment
• Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia
• Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample
• Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings
• Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
• The induction of synaesthesia with chemical agents: a systematic review
• Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine
• Can psychedelic compounds play a part in drug dependence therapy?
• Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience
• Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination
• Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame
• Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis
• Trends in the Top-Cited Articles on Classic Psychedelics
• More realistic forecasting of future life events after psilocybin for treatment-resistant depression
• Neurometabolic effects of psilocybin, (MDE) and d-methamphetamine in healthy volunteers
• Psychedelics as a treatment for disorders of consciousness
• Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users
• Taking Psychedelics Seriously
• Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions
• Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders
• Is LSD toxic?
• Psilocybin: from ancient magic to modern medicine
• Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology
• Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short-and long-term outcomes and current psychological functioning
• Psychedelics and the science of self-experience
• Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects
• Serotonergic psychedelics temporarily modify information transfer in humans
• A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment
• Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study
• Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons
• Experienced drug users assess the relative harms and benefits of drugs: a web-based survey
• The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations
• Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs
• A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?
• Harm potential of magic mushroom use: A review
• Consumption of Ayahuasca by Children and Pregnant Women: Medical Controversies and Religious Perspectives
• β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer’s Disease-Related Sites
• In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin 2A Receptor Binding in MDMA and Hallucinogen Users
• Heaven and Hell—A Phenomenological Study of Recreational Use of 4-HO-MET in Sweden
• A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment
• The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability
• The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
• Finding the self by losing the self: Neural correlates of ego‐dissolution under psilocybin
• Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis
• Altered network hub connectivity after acute LSD administration
• Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress
• Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016
• LSD modulates music-induced imagery via changes in parahippocampal connectivity
• Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges
• LSD alters eyes‐closed functional connectivity within the early visual cortex in a retinotopic fashion
• Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives
• Posttraumatic Stress Disorder After a Psychedelic Experience, a Case Report
• LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation
• Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
• Bringing Ayahuasca to the Clinical Research Laboratory
• Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain
• Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD
• Cannabinoids is a “No-Go” While a Cancer Patient is on Immunotherapy; but is It Safe to Use Psychedelics During Cancer Immunotherapy?
• Replication and extension of a model predicting response to psilocybin
• Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis
• Can MDMA Play a Role in the Treatment of Substance Abuse?
• Salvia divinorum: A Psychopharmacological Riddle and a Mind-Body Prospect
• The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor
• Potential Therapeutic Effects of Psilocybin
• Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD
• Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory
• The hidden therapist: evidence for a central role of music in psychedelic therapy
• Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide
• Tripping on nothing: placebo psychedelics and contextual factors
• Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience
• Psychedelics and Psychedelic-Assisted Psychotherapy
• Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin
• Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
• Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
• Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals
• An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis
• Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence
• Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline
• A review of the clinical effects of psychotomimetic agents
• Psychedelics and dying care: A historical look at the relationship between psychedelics and palliative care
• Reactions to psilocybin administered in a supportive environment
• Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder
• Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains
• Decreased directed functional connectivity in the psychedelic state
• A placebo-controlled investigation of synaesthesia-like experiences under LSD
• Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada
• Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
• A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity
• Hallucinogen persisting perception disorder: what do we know after 50 years?
• Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin
• The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions
• Psychedelic Communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness
• Use of psilocybin (“mushrooms”) among US adults: 2015–2018
• Effects of Schedule I drug laws on neuroscience research and treatment innovation
• Peak Experiences of Psilocybin Users and Non-Users
• Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression
• Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin
• Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation
• Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
• Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected
• Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions
• Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD
• Semantic activation in LSD: evidence from picture naming
• User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study
• Predicting responses to psychedelics: a prospective study
• Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine
• Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
• Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
• Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
• A clinical study of LSD treatment in alcoholism
• Treating drug dependence with the aid of ibogaine: a qualitative study
• Effects of LSD on music-evoked brain activity
• Revisiting Wasson’s Soma: Exploring the Effects of Preparation on the Chemistry of Amanita Muscaria
• LSD in the supportive care of the terminally ill cancer patient
• Mechanisms of antiaddictive actions of ibogaine
• Drugs as instruments: A new framework for non-addictive psychoactive drug use
• Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers
• Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca
• Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
• A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010
• Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca
• Genuine and drug-induced synesthesia: a comparison
• Health status of ayahuasca users
• Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament
• Dissolving the self: Active inference, psychedelics, and ego-dissolution
• The peak experience variable in DPT-assisted psychotherapy with cancer patients
• An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders
• Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK
• Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
• The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology
• Common neural signatures of psychedelics: frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition
• Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
• Ketamine psychedelic therapy (KPT): a review of the results of ten years of research
• A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study
• Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence: qualitative results
• Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders
• A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders
• ‘Hitting highs at rock bottom’: LSD treatment for alcoholism, 1950–1970
• Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale
• Flashback: psychiatric experimentation with LSD in historical perspective
• Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram
• Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion
• Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
• Culture and psychedelic psychotherapy: Ethnic and racial themes from three Black women therapists
• Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report
• Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
• Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression
• Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin
• Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum
• Classic hallucinogens in the treatment of addictions
• Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
• Psilocybin and MDMA reduce costly punishment in the Ultimatum Game
• Increased thalamic resting state connectivity as a core driver of LSD-induced hallucinations
• Psychedelics, personality and political perspectives
• Attenuation and anticipation: A therapeutic use of lysergic acid diethylamide
• Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction
• An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
• Ayahuasca in adolescence: a neuropsychological assessment
• MDMA enhances emotional empathy and prosocial behavior
• Low dose ketamine reduces pain perception and blood pressure, but not muscle sympathetic nerve activity, responses during a cold pressor test
• Ayahuasca in adolescence: Qualitative results
• Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans
• Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
• Ayahuasca in adolescence: a preliminary psychiatric assessment
• Do hallucinogens cause residual neuropsychological toxicity?
• Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers
• Can psychedelics have a role in psychiatry once again?
• Dose-response study of N,N-dimethyltryptamine in humans: subjective effects and preliminary results of a new rating scale
• Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
• The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions
• Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
• LSD flattens the functional hierarchy of the human brain
• Altered insula connectivity under MDMA
• Longterm effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
• The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network
• Pharmacokinetics of Hoasca alkaloids in healthy humans
• The psychopharmacology of hallucinogens
• Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics
• Influence of Lysergic Acid Diethylamide (LSD-25) on Subjective Time
• Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors
• Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers
• Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans
• Psychedelics and the human receptorome
• Psychedelics and connectedness
• Microdosing psychedelics: Motivations, subjective effects and harm reduction
• Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
• Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, peyote, ibogaine and ayahuasca
• N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function
• Therapeutic infusions of ketamine: do the psychoactive effects matter?
• Animal models of serotonergic psychedelics
• Management of treatment-resistant depression: Challenges and strategies
• A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
• MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?
• Long-term effects of psychedelic drugs: A systematic review
• The Emerging Role of Psilocybin and MDMA in the Treatment of Mental Illness
• Modern clinical research on LSD
• MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor
• Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder
• Assessment of addiction severity among ritual users of ayahuasca
• Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
• Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
• The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports
• Subjective reports of the effects of MDMA in a clinical setting
• Psychedelics and the essential importance of context
• Perception is in the Details: A Predictive Coding Account of the Psychedelic Phenomenon
• Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
• Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception
• LSD acutely impairs fear recognition and enhances emotional empathy and sociality
• Effects of psilocybin on time perception and temporal control of behaviour in humans
• Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
• A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
• Reviewing the potential of psychedelics for the treatment of PTSD
• The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review
• Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
• Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale psychiatric hospital
• 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
• Characterization of behavioral and endocrine effects of LSD on zebrafish
• Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
• Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire
• Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study
• Is Ecstasy an “Empathogen”? Effects of ±3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others
• Glutamatergic Model Psychoses: Prediction Error, Learning, and Inference
• Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
• Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users
• Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube
• DARK Classics in Chemical Neuroscience: Psilocybin
• DARK Classics in Chemical Neuroscience: Ibogaine
• Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
• Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy
• Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
• The use of the psychological flexibility model to support psychedelic assisted therapy
• Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
• Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial
• Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience
• Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
• Entheogenic Experience and Spirituality
• Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers
• The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity
• Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences
• The History of Psychedelics in Psychiatry
• Psychedelics and Psychotherapy
• The ritual use of ayahuasca during treatment of severe physical illnesses: a qualitative study
• Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations
• Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism
• How psychedelic researchers’ self-admitted substance use and their association with psychedelic culture affect people’s perceptions of their scientific integrity and the quality of their research
• A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis
• Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy
• Investigation of the Structure–Activity Relationships of Psilocybin Analogues
• LSD alters dynamic integration and segregation in the human brain
• Constructing drug effects: a history of set and setting
• Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors
• MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
• Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study
• Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans
• Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine
• MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial
• The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
• The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
• Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
• Ketamine in Bipolar Disorder: A Review
• Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
• Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination
• A non-hallucinogenic psychedelic analogue with therapeutic potential
• The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health
• Effects of psilocybin therapy on personality structure
• A consensus statement on the use of ketamine in the treatment of mood disorders
• Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
• Ibogaine in the treatment of substance dependence
• The ibogaine medical subculture
• Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
• Effects of MDMA on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting
• Effects of the psychedelic amphetamine MDA (3, 4-methylenedioxyamphetamine) in healthy volunteers
• Role of Serotoninergic Neurons and 5-HT Receptors in the Action of Hallucinogens
• Whole-brain multimodal neuroimaging model using serotonin receptor maps explains non-linear functional effects of LSD
• Serotonin and brain function: a tale of two receptors
• Serotonin and serotonin receptors in hallucinogen action
• MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens
• Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy
• Pivotal Mental States
• Effects of external stimulation on psychedelic state neurodynamics
• Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
• Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects
• Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
• Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
• Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
• Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey
• Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review
• Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
• Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
• The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine
• The use of psychedelic agents with autistic schizophrenic children
• Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects
• Turn On, Tune In, Drop In: Psychedelics, Creativity and Entrepreneurship
• Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies
• LSD enhances the emotional response to music
• Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
• Psychedelics promote structural and functional neural plasticity
• Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial
• Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation
• Patients’ accounts of increased connectedness and acceptance after psilocybin for treatment-resistant depression
• Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
• Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study
• Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat
• Psychedelics and schizophrenia
• LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects
• Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
• Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials
• Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms
• LSD enhances suggestibility in healthy volunteers
• The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories
• Comparison of Rapid Antidepressant and Antisuicidal Effects of Intramuscular Ketamine, Oral Ketamine, and Electroconvulsive Therapy in Patients With Major Depressive Disorder
• Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
• LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm
• DMT models the near-death experience
• [RETRACTED] A mechanistic model of the neural entropy increase elicited by psychedelic drugs
• The paradoxical psychological effects of lysergic acid diethylamide (LSD)
• Increased global functional connectivity correlates with LSD-induced ego dissolution
• Ayahuasca’s entwined efficacy: an ethnographic study of ritual healing from ‘addiction’
• Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
• Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
• Psychedelics: Where we are now, why we got here, what we must do
• Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry
• Psychedelics and mental health: a population study
• DMT alters cortical travelling waves
• The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
• Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences
• Acute subjective effects in LSD- and MDMA-assisted psychotherapy
• A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding
• The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD
• MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
• Acute effects of lysergic acid diethylamide in healthy subjects
• Psychedelics as a Novel Approach to Treating Autoimmune Conditions
• Severe Neurological Sequelae after a Recreational Dose of LSD
• Post-acute psychological effects of classical serotonergic psychedelics: A systematic review and meta-analysis
• Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences
• The therapeutic potential of psychedelic drugs: past, present, and future
• Unifying theories of psychedelic drug effects
• Psychedelic medicine: The biology underlying the persisting psychedelic effects
• How do psychedelics work?
• Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
• Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study
• Chronic pain and psychedelics: a review and proposed mechanism of action
• Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity
• Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
• Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin
• Psychometric evaluation of the altered states of consciousness rating scale (OAV)
• Psilocybin biases facial recognition, goal-directed behaviour, and mood state toward positive relative to negative emotions through different serotonergic subreceptors
• Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan
• Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans
• 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial
• Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
• Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers
• Psychedelics in the treatment of unipolar mood disorders: a systematic review
• Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca
• Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT 2 and 5-HT 1 receptors
• Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine
• Accounting for Microdosing Classic Psychedelics
• Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA
• Neural correlates of the LSD experience revealed by multimodal neuroimaging
• Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression
• Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)
• Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression
• Psychedelics, meditation, and self-consciousness
• Psychedelics as Medicines: An Emerging New Paradigm
• The effects of acutely administered 3, 4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level–dependent resting state functional connectivity
• The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain
• Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities
• MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
• Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study
• Gender differences in the subjective effects of MDMA
• Positive psychology in the investigation of psychedelics and entactogens: A critical review
• Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
• The therapeutic potential of microdosing psychedelics in depression
• Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants
• Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison
• Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
• The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training
• Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth
• Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
• Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
• Emotions and brain function are altered up to one month after a single high dose of psilocybin
• Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley.
• Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans
• MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder
• Acute effects of 3, 4-methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol
• Classic psychedelics as therapeutics for psychiatric disorders
• Acute effects of psilocybin on glutamate concentration levels, functional connectivity and subjective state
• Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
• Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer
• The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
• Blockade of 5-HT 2 receptor selectively prevents MDMA-induced verbal memory impairment
• Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision
• Dr. Leary’s Concord Prison Experiment: A 34-Year Follow-up Study
• Multifaceted empathy of healthy volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies
• Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder
• LSD Overdoses: Three Case Reports
• Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions
• Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music
• Classic hallucinogens and mystical experiences: phenomenology and neural correlates
• LSD-induced increases in social adaptation to opinions similar to one’s own are associated with stimulation of serotonin receptors
• Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers
• Human hallucinogen research: guidelines for safety
• Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
• The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
• Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers
• Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia
• Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
• A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
• P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap
• Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging
• Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
• The psychological and human brain effects of music in combination with psychedelic drugs
• Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews
• Long-lasting subjective effects of LSD in normal subjects
• Serotonergic psychedelics and personality: A systematic review of contemporary research
• Psychiatry & the psychedelic drugs. Past, present & future
• The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation
• Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
• A systematic study of microdosing psychedelics
• Psychedelics
• The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis
• Acute effects of lyserlon acid diethylamide (LSD) on resting brain function
• Neuropharmacological modulation of the aberrant bodily self through psychedelics
• Psychedelic drugs-a new era in psychiatry?
• Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
• Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans
• Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
• Psilocybin, psychological distress, and suicidality
• Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder
• A potential role for psilocybin in the treatment of obsessive-compulsive disorder
• Long-term Follow-Up Outcomes of MDMA-assisted Psychotherapy for Treatment of PTSD: A Longitudinal Pooled Analysis of Six Phase 2 Trials
• A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
• Out of the box: A psychedelic model to study the creative mind
• Jekyll and Hyde Revisited: Paradoxes in the Appreciation of Drug Experiences and Their Effects on Creativity
• Self-Reported Drug Use and Creativity: (Re)Establishing Layperson Myths
• Breakdown or Breakthrough? A History of European Research into Drugs and Creativity
• Updating the dynamic framework of thought: Creativity and psychedelics
• The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity
• LSD and Creativity
• Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
• Psychedelic Agents in Creative Problem-Solving: A Pilot Study
• Psychedelic Drugs and Creativity
• A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)- assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)
• Psychedelics and Creativity: a Review of the Quantitative Literature
• Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin
• Enhancement of Creative Expression and Entoptic Phenomena as After-Effects of Repeated Ayahuasca Ceremonies
• Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
• The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving
• Psychedelics and holistic thinking: a tool for science
• Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
• Is it time to revisit the role of psychedelic drugs in enhancing human creativity?
• Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
• Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
• Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis
• Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
• From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner
• Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression
• Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
• Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications
• Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
• Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
• Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
• Serotonin, psychedelics and psychiatry
• Prediction of psilocybin response in healthy volunteers
• Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology
• The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial
• Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study
• Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
• Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial
• Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings
• Psilocybin induces time-dependent changes in global functional connectivity: Psi-induced changes in brain connectivity
• Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
• Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
• In vivo production of psilocybin in E. coli
• Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer
• Hallucinogens
• Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
• Adverse Reactions to Psychedelic Drugs – A Review of the Literature
• Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
• The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
• The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
• Psychedelics and music: neuroscience and therapeutic implications
• Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
• Psychiatry might need some psychedelic therapy
• Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
• Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
• Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition
• Long-term follow-up of psilocybin-facilitated smoking cessation
• Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
• Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
• Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
• Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
• The entropic brain – revisited
• The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
• REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
• 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
• Neural correlates of the DMT experience assessed via multivariate EEG
• Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance